Reviewing the use of antipsychotic drugs in people with intellectual disability (Q36353795)

13 August 2017

1 reference

title

Reviewing the use of antipsychotic drugs in people with intellectual disability (English)

1 reference

13 August 2017

0 references

Marco Bertelli

3

0 references

author name string

Giampaolo La Malfa

series ordinal

1

1 reference

13 August 2017

Stefano Lassi

series ordinal

2

1 reference

13 August 2017

Alessandro Castellani

series ordinal

4

1 reference

13 August 2017

publication date

1 March 2006

1 reference

13 August 2017

published in

Human Psychopharmacology

1 reference

13 August 2017

volume

21

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

73-89

1 reference

Effects of thioridazine on the intellectual performance of mentally retarded drug responders and nonresponders.

13 August 2017

cites work

1 reference

Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome

21 January 2018

1 reference

Haloperidol in emotionally disturbed mentally retarded individuals

21 January 2018

1 reference

Sedation of difficult-to-sedate children undergoing MR imaging: value of thioridazine as an adjunct to chloral hydrate

21 January 2018

1 reference

Corneal and lenticular opacities in mentally retarded young adults treated with thioridazine and chlorpromazine

21 January 2018

1 reference

Differential response of operant self-injury to pharmacologic versus behavioral treatment

21 January 2018

1 reference

Use of Psychotropic Medications for Persons With Mental Retardation Who Live in Oklahoma Nursing Homes

21 January 2018

1 reference

Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation

21 January 2018

1 reference

7 January 2021

Dental use of meprobamate and promazine hydrochloride for mentally retarded and emotionally disturbed patients. A preliminary report.

1 reference

7 January 2021

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

7 January 2021

Clinical effects of methylphenidate and thioridazine in intellectually subaverage children

1 reference

7 January 2021

Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents

1 reference

7 January 2021

Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities

1 reference

7 January 2021

Clozapine treatment in a population of adults with mental retardation

1 reference

7 January 2021

Recurrent neuroleptic malignant syndrome in a man with mild mental handicap

1 reference

7 January 2021

Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study

1 reference

7 January 2021

Clopenthixol in aggressive mentally handicapped patients

1 reference

7 January 2021

The prescribing of neuroleptic drugs for people with learning disabilities living in Leicestershire.

1 reference

7 January 2021

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid

1 reference

7 January 2021

Effects of thioridazine and withdrawal dyskinesias on workshop performance of mentally retarded young adults

1 reference

7 January 2021

Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials

1 reference

7 January 2021

Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior

1 reference

7 January 2021

Droperidol in the management of hyperactivity, self-mutilation and aggression in mentally handicapped patients

1 reference

7 January 2021

Use of Clozapine in 10 Mentally Retarded Adults

1 reference

7 January 2021

Second-generation antipsychotic medications in children and adolescents

1 reference

7 January 2021

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.

1 reference

7 January 2021

Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.

1 reference

7 January 2021

Current status of antipsychotic treatment

1 reference

7 January 2021

Psychiatry of Elderly Compared to Younger Adults with Intellectual Disabilities

1 reference

7 January 2021

Unusual compulsive motor activity during treatment with clothiapine in a mentally retarded adolescent.

1 reference

7 January 2021

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism

1 reference

7 January 2021

Risperidone in Young Children with Pervasive Developmental Disorders and Other Developmental Disabilities

1 reference

7 January 2021

Catatonic syndrome following recovery from neuroleptic malignant syndrome

1 reference

7 January 2021

General anaesthesia for the mentally handicapped. A study based on anaesthesia for dental surgery

1 reference

7 January 2021

A case of neuroleptic malignant syndrome in a mentally retarded adolescent

1 reference

7 January 2021

Risperidone-induced obsessive-compulsive symptoms in two children

1 reference

7 January 2021

Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent

1 reference

7 January 2021

Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function

1 reference

7 January 2021

‘Pfropfschizophrenie’ revisited

1 reference

7 January 2021

Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review

1 reference

7 January 2021

Risperidone in Prader-Willi syndrome

1 reference

7 January 2021

Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation

1 reference

7 January 2021

Psychopharmacologic treatment of pathologic aggression

1 reference

7 January 2021

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

1 reference

7 January 2021

Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center.

1 reference

7 January 2021

Neuroleptic-induced dementia documented in four adults with mental retardation

1 reference

7 January 2021

Brief report: haloperidol treatment of trichotillomania in a boy with autism and mental retardation

1 reference

7 January 2021

Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome

1 reference

7 January 2021

Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation

1 reference

7 January 2021

Results of barbiturate antiepileptic drug discontinuation on antipsychotic medication dose in individuals with intellectual disability

1 reference

7 January 2021

A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy

1 reference

7 January 2021

Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone

1 reference

7 January 2021

Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals

1 reference

7 January 2021

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

1 reference

7 January 2021

Diagnosis and treatment of a severe psychotic illness in a man with dual severe sensory impairments caused by the presence of Usher syndrome

1 reference

7 January 2021

Psychotropic medication in adults with mental retardation: prevalence, and prescription practices

1 reference

7 January 2021

Risperidone and explosive aggressive autism

1 reference

7 January 2021

Prevalence of eating disorders in adults with mental retardation living in the community

1 reference

7 January 2021

Patients with and without intellectual disability seeking outpatient psychiatric services: diagnoses and prescribing pattern

1 reference

7 January 2021

Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.

1 reference

7 January 2021

Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults

1 reference

7 January 2021

The use of anti‐psychotic drugs with adults with learning disabilities and challenging behaviour

1 reference

7 January 2021

Personal Characteristics Associated With Episodes of Injury in a Residential Facility

1 reference

7 January 2021

Open-label olanzapine treatment in five preadolescent children

1 reference

7 January 2021

Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent

1 reference

7 January 2021

Effects of neuroleptic and anticonvulsant drugs on repeated acquisition learning in microencephalic and normal rats

1 reference

7 January 2021

Pipothiazine palmitate in the management of aggressive mentally handicapped patients

1 reference

7 January 2021

Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients.

1 reference

7 January 2021

Obesity in people with intellectual disabilities: the impact of nurse-led health screenings and health promotion activities.

1 reference

7 January 2021

Open-label quetiapine in the treatment of children and adolescents with autistic disorder

1 reference

7 January 2021

Psychopharmacology and mental retardation: a 10 year review (1990-1999).

1 reference

7 January 2021

Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions

1 reference

7 January 2021

A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication

1 reference

7 January 2021

Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability

1 reference

7 January 2021

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study

1 reference

7 January 2021

Pharmacological management of challenging behavior of individuals with intellectual disability.

1 reference

7 January 2021

Clopenthixol decanoate in the management of aggressive mentally handicapped patients

1 reference

7 January 2021

Psychiatric symptoms in adults with learning disability and challenging behaviour

1 reference

7 January 2021

Grey zones of clinical practice: some limits to evidence-based medicine.

1 reference

7 January 2021

Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency

1 reference

7 January 2021

Psychotropic drug use among people with intellectual disability before and after deinstitutionalization

1 reference

7 January 2021

Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation

1 reference

7 January 2021

Behavior disorders in persons with mental retardation receiving antipsychotic medication

1 reference

7 January 2021

Auto-amputation of the tongue associated with flupenthixol induced extrapyramidal symptoms

1 reference

7 January 2021

Risperidone in Children and Adolescents with Pervasive Developmental Disorder: Pilot Trial and Follow-Up

1 reference

7 January 2021

Malignant neuroleptics syndrome

1 reference

7 January 2021

Risperidone in the treatment of pervasive developmental disorder

1 reference

7 January 2021

The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients

1 reference

7 January 2021

Reserpine, chlorpromazine and the mentally retarded. A report on 139 cases.

1 reference

7 January 2021

Does risperidone have a place in the treatment of nonschizophrenic patients?

1 reference

7 January 2021

Nothing new under the sun: clozapine rechallenge following a life-threatening medical event in a patient with psychiatric illness and developmental disability

1 reference

7 January 2021

A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders

1 reference

7 January 2021

A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders

1 reference

7 January 2021

Effects of thioridazine and visual screening on stereotypy and social behavior in individuals with mental retardation

1 reference

7 January 2021

Pharmacological treatment of self-injurious behavior in mentally retarded persons

1 reference

7 January 2021

Behavioral monitoring of pharmacological interventions for self-injury

1 reference

7 January 2021

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

1 reference

7 January 2021

Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.

1 reference

7 January 2021

Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: an open-label study.

1 reference

7 January 2021

Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders

1 reference

7 January 2021

Psychotropic drug use in intellectually disabled group-home residents with behavioural problems

1 reference

7 January 2021

The use of clozapine in adults with intellectual disability

1 reference

7 January 2021

Thioridazine: Re-evaluating the Risk/Benefit Equation

1 reference

7 January 2021

Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior

1 reference

7 January 2021

Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

1 reference

7 January 2021

Olanzapine treatment in an organic hallucinosis patient

1 reference

7 January 2021

Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects

1 reference

7 January 2021

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

1 reference

7 January 2021

Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up

1 reference

7 January 2021

Risperidone as add‐on therapy in behavioural disturbances in mental retardation: a double‐blind placebo‐controlled cross‐over study

1 reference

7 January 2021

The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients.

1 reference

7 January 2021

Pimozide treatment in disruptive severely retarded patients

1 reference

7 January 2021

Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

1 reference

7 January 2021

Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation

1 reference

7 January 2021

Haloperidol-induced rhabdomyolysis without neuroleptic malignant syndrome in a handicapped child

1 reference

7 January 2021

Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.748

1 reference

13 August 2017

1 reference